STANFORD UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1885-11-11

Employees: 10K

Market Cap: -

Website: http://www.stanford.edu

Clinical Trials

Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

Phase 2

Withdrawn

Conditions: Leukemia
Acute Lymphocytic Leukemia

First Posted Date: 2010-07-14

Last Posted Date: 2018-05-21

Lead Sponsor: Stanford University

Registration Number: NCT01162031

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Outcome Measures in Infant/Early Childhood Lung Disease w/ Chest CT Scanning & Lung Function Testing

Completed

Conditions: Lung Cancer

First Posted Date: 2010-07-08

Last Posted Date: 2013-04-04

Lead Sponsor: Stanford University

Target Recruit Count: 30

Registration Number: NCT01158495

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Filter Initial & Long Term Evaluation After Placement and Retrieval Registry

Recruiting

Conditions: Venous Thromboembolism

Interventions: Procedure: IVC Filter Placement or Retrieval

First Posted Date: 2010-07-08

Last Posted Date: 2020-05-12

Lead Sponsor: Stanford University

Target Recruit Count: 5000

Registration Number: NCT01158482

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin
Lymphoma, T-Cell, Peripheral
Bone Marrow Transplant Failure

Interventions: Drug: Nilotinib

First Posted Date: 2010-07-02

Last Posted Date: 2020-04-15

Lead Sponsor: Stanford University

Target Recruit Count: 33

Registration Number: NCT01155817

Locations: 🇨🇦
Gordon and Leslie Diamond Health Care Centre Hematology Administration, Vancouver, British Columbia, Canada
🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 2 locations

Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

Phase 4

Completed

Conditions: Kidney Diseases

Interventions: Drug: H.P. Acthar Gel

First Posted Date: 2010-07-01

Last Posted Date: 2014-09-01

Lead Sponsor: Stanford University

Target Recruit Count: 15

Registration Number: NCT01155141

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma

Phase 2

Withdrawn

Conditions: Eye Cancer
Retinoblastoma

First Posted Date: 2010-06-28

Last Posted Date: 2012-05-14

Lead Sponsor: Stanford University

Registration Number: NCT01151748

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

Phase 2

Terminated

Conditions: Cholangiocarcinoma
Hepatobiliary Neoplasm
Liver Cancer
Bile Duct Cancer
Cancer of Gallbladder

Interventions: Procedure: Stereotactic Body Radiotherapy
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin
Drug: Capecitabine
Drug: 5FU
Procedure: Liver transplantation

First Posted Date: 2010-06-28

Last Posted Date: 2016-07-29

Lead Sponsor: Stanford University

Target Recruit Count: 2

Registration Number: NCT01151761

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

School Response to Families Who Have Children With Cancer

Withdrawn

Conditions: Carcinomas
Squamous Cell Carcinoma
Adenocarcinoma

First Posted Date: 2010-06-22

Last Posted Date: 2017-06-26

Lead Sponsor: Stanford University

Registration Number: NCT01148082

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Device: CyberKnife based stereotactic radiotherapy
Drug: Gemcitabine
Drug: Fludeoxyglucose (18F) (FDG)

First Posted Date: 2010-06-17

Last Posted Date: 2017-12-19

Lead Sponsor: Stanford University

Target Recruit Count: 59

Registration Number: NCT01146054

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry

Terminated

Conditions: Myeloproliferative Disorders (MPD)
Myeloproliferative Disorders

First Posted Date: 2010-06-16

Last Posted Date: 2020-04-09

Lead Sponsor: Stanford University

Target Recruit Count: 10

Registration Number: NCT01144780

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy